Recent Finacing
Recent Raise
MediWound is an Israeli biopharma developing enzymatic therapeutics—FDA-approved NexoBrid for burn eschar removal, temperature-stable field formulation with DoD, Phase III-ready EscharEx for chronic wound debridement.
Focus Areas
See the team members at MediWound.
